X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (114935) 114935
Book Review (27128) 27128
Publication (7326) 7326
Newsletter (3606) 3606
Newspaper Article (569) 569
Magazine Article (385) 385
Conference Proceeding (345) 345
Book / eBook (278) 278
Book Chapter (213) 213
Transcript (91) 91
Dissertation (52) 52
Trade Publication Article (40) 40
Web Resource (35) 35
Paper (9) 9
Data Set (8) 8
Streaming Video (8) 8
Reference (7) 7
Presentation (5) 5
Report (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (105680) 105680
index medicus (104081) 104081
female (59727) 59727
male (50167) 50167
oncology (48029) 48029
middle aged (44343) 44343
antineoplastic agents - adverse effects (39969) 39969
aged (38098) 38098
cancer (36139) 36139
adult (35368) 35368
antineoplastic agents - therapeutic use (31812) 31812
chemotherapy (31794) 31794
treatment outcome (22714) 22714
antineoplastic combined chemotherapy protocols - therapeutic use (21249) 21249
care and treatment (18304) 18304
antineoplastic agents (18153) 18153
animals (18025) 18025
antimitotic agents (16143) 16143
antineoplastic agents - administration & dosage (15912) 15912
antineoplastic combined chemotherapy protocols - adverse effects (14777) 14777
neoplasms - drug therapy (14254) 14254
pharmacology & pharmacy (14183) 14183
aged, 80 and over (12508) 12508
research (12122) 12122
therapy (11976) 11976
medicine & public health (11023) 11023
hematology (10756) 10756
breast neoplasms - drug therapy (10612) 10612
antineoplastic agents - pharmacology (10183) 10183
analysis (9293) 9293
drug therapy (9035) 9035
health aspects (8967) 8967
retrospective studies (8680) 8680
adolescent (8615) 8615
disease-free survival (8272) 8272
abridged index medicus (7952) 7952
prognosis (7933) 7933
drug administration schedule (7894) 7894
risk factors (7871) 7871
breast cancer (7702) 7702
dose-response relationship, drug (7526) 7526
combined modality therapy (7487) 7487
lung neoplasms - drug therapy (7473) 7473
neoplasm staging (7391) 7391
hematology, oncology and palliative medicine (7190) 7190
mice (7179) 7179
cisplatin (7148) 7148
tumors (6967) 6967
survival (6948) 6948
metastasis (6804) 6804
child (6779) 6779
clinical trials (6545) 6545
trial (6531) 6531
toxicity (6264) 6264
survival rate (6155) 6155
time factors (6063) 6063
survival analysis (6054) 6054
antineoplastic combined chemotherapy protocols - administration & dosage (5908) 5908
radiotherapy (5902) 5902
follow-up studies (5869) 5869
apoptosis (5840) 5840
cell line, tumor (5791) 5791
clinical trials as topic (5698) 5698
carcinoma (5689) 5689
surgery (5079) 5079
prospective studies (5019) 5019
cisplatin - administration & dosage (4963) 4963
young adult (4909) 4909
oncology, experimental (4877) 4877
carcinoma, non-small-cell lung - drug therapy (4746) 4746
paclitaxel (4606) 4606
article (4592) 4592
neoplasm metastasis (4477) 4477
cancer therapies (4416) 4416
patients (4337) 4337
breast neoplasms - pathology (4272) 4272
breast-cancer (4245) 4245
child, preschool (4230) 4230
deoxycytidine - analogs & derivatives (4162) 4162
chemotherapy, adjuvant (4140) 4140
medical research (4140) 4140
quality of life (4123) 4123
phase-ii (4105) 4105
complications and side effects (4066) 4066
disease progression (4044) 4044
fluorouracil - administration & dosage (3989) 3989
cisplatin - adverse effects (3969) 3969
pharmacology/toxicology (3967) 3967
antineoplastic agents - pharmacokinetics (3930) 3930
drugs (3930) 3930
dosage and administration (3923) 3923
drug therapy, combination (3872) 3872
expression (3842) 3842
cancer research (3798) 3798
medicine, general & internal (3732) 3732
apoptosis - drug effects (3717) 3717
docetaxel (3697) 3697
combination (3690) 3690
doxorubicin (3688) 3688
leukemia (3688) 3688
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (158) 158
Online Resources - Online (36) 36
Collection Dvlpm't (Acquisitions) - Vendor file (14) 14
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (13) 13
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
Chemistry (A D Allen) - Stacks (4) 4
Credit Valley Hospital - Special Collections (1) 1
Credit Valley Hospital - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
East Asian (Cheng Yu Tung) - Reference (1) 1
Gerstein Science - Circulation Desk (1) 1
Lakeridge Health Sciences - Online (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - Online (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Missing (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (111968) 111968
Japanese (1959) 1959
French (1570) 1570
German (1474) 1474
Spanish (509) 509
Chinese (482) 482
Russian (434) 434
Italian (383) 383
Polish (234) 234
Hungarian (146) 146
Dutch (144) 144
Czech (126) 126
Danish (121) 121
Swedish (76) 76
Norwegian (71) 71
Portuguese (48) 48
Finnish (45) 45
Hebrew (36) 36
Croatian (25) 25
Korean (23) 23
Slovak (23) 23
Bulgarian (17) 17
Romanian (16) 16
Ukrainian (16) 16
Serbian (14) 14
Turkish (13) 13
Lithuanian (2) 2
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment (goserelin plus tamoxifen or anastrozole) in premenopausal women... 
RECEIVING ADJUVANT LETROZOLE | MULTIPLE-MYELOMA | OVARIAN ABLATION | BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | DELTA-T-CELLS | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2004, Volume 15, Issue 3, pp. 460 - 466
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1344 - 1354
Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy... 
Hematology, Oncology and Palliative Medicine | CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | LIVER-TRANSPLANTATION | RISK-FACTORS | THERAPY | MANAGEMENT | ONCOLOGY | SAFETY | PREVENTION | RECURRENCE | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents | Index Medicus
Journal Article
Annals of Allergy, Asthma & Immunology, ISSN 1081-1206, 2010, Volume 105, Issue 4, pp. 259 - 273.e78
Journal Article